Thess

Thess (also referred to as Thess Corporate) is a French medical technology company focused on digital medical devices for telemonitoring (télésurveillance médicale) and secure connected medication management. The company was created in 2021 by La Sas La Valériane, which in 2022 contributed its IT business division — including the CE class I Thess Monitoring medical device and the Thess Device research programme with its patent — to the new entity. Thess positions itself at the intersection of medicine and digital communication, aiming to make the digitalisation of the doctor–patient relationship an opportunity for better and safer patient care during treatment. Thess develops and deploys two main product lines. Thess Device is a connected and secure medical device for medication intake, designed to support patients in following their treatment correctly. Thess Monitoring is a medical telemonitoring device used in several therapeutic areas, including nephrology (chronic kidney disease, dialysis, transplant), oncology, post-breast-cancer-surgery follow-up, and post-surgical pain management in outpatient settings. The company states that medical telemonitoring has, over 25 years, proven its ability to facilitate the medical organisation of follow-up for a growing and increasingly non-hospitalised patient population, improve patients' quality of life during treatment, reduce stress in communicating with their doctor, and support patient empowerment and engagement in their own treatment. Thess operates in France and internationally. Its telemonitoring solution for chronic kidney disease, dialysis and transplant has obtained a reimbursement code (6654493) in the French system. The company has engaged clinical studies, including Beautify (telemonitoring during the six months following breast cancer surgery for patients undergoing cancer treatment) and Prolife (telemonitoring during 18 months of cancer treatment for patients on oral therapy). It has also presented Thess Monitoring Antalgeek, described as a digital medical device for telemonitoring dedicated to pain follow-up after surgery, presented as a world first aiming to secure patients' return home while preventing the risk of pain chronicisation. Thess has received public support: its project was financed by the French State under the France 2030 programme (industrialisation and export components) and by the European Union — Next Generation EU — under the France Relance plan. The company's stated values are expertise, humanism and responsibility. Its leadership emphasises that in a world where communication increasingly relies on digital tools, the doctor–patient relationship must adapt, and Thess's ambition is to ensure this evolution benefits care quality and patient safety.

Thess Corporate was created in 2021 by La Sas La Valériane. In 2022, La Valériane contributed its IT business division to Thess, including the CE class I Thess Monitoring medical device and the Thess Device research programme together with its patent. This transfer gave the young company both a marketable telemonitoring device and a patented pipeline for connected medication management. In 2023, Thess engaged two clinical studies. The Beautify study concerns medical telemonitoring during the six months following breast surgery for patients undergoing cancer treatment. The Prolife study concerns medical telemonitoring during 18 months of cancer treatment for patients on oral therapy. These studies reflect the company's strategy of building clinical evidence across oncology and post-surgical care pathways. The company has since expanded its telemonitoring applications to nephrology — chronic kidney disease, dialysis and transplant — for which it obtained a reimbursement code (6654493) in the French system. It has also developed Thess Monitoring Antalgeek, a digital medical device for telemonitoring dedicated to pain follow-up after surgery, presented as a world first intended to secure patients' return home while preventing the risk of pain chronicisation. Thess has received public financing: its project was financed by the French State under France 2030 (industrialisation and export components) and by the European Union — Next Generation EU — under the France Relance plan. The company operates in France and internationally and describes its values as expertise, humanism and responsibility. Its leadership frames the company's mission around adapting the doctor–patient relationship to digital communication in order to better care for and secure patients during treatment.

• 2023

  Engagement of the Beautify clinical study (telemonitoring during the six months following breast surgery for patients undergoing cancer treatment).

• 2023

  Engagement of the Prolife clinical study (telemonitoring during 18 months of cancer treatment for patients on oral therapy).

• 2022

  La Valériane contributes its IT business division, including the CE class I Thess Monitoring medical device and the Thess Device research programme with its patent.

• 2021

  Creation of Thess Corporate by La Sas La Valériane.

Digital medical devices for medical telemonitoring and secure medication management, combining expertise, humanism and responsibility to improve and secure patient care during treatment.

• Thess Device

  Connected and secure medical device for medication intake.

• Thess Monitoring

  Medical telemonitoring device used in nephrology (chronic kidney disease, dialysis, transplant), oncology, post-breast-cancer-surgery follow-up, and post-surgical pain management in outpatient settings.

• Thess Monitoring Antalgeek

  Digital medical device for telemonitoring dedicated to pain follow-up after surgery, presented as a world first aiming to secure patients' return home while preventing the risk of pain chronicisation.

1. 1Thess Corporatethess-corp.fr
2. 2Histoire - Thess Corporatethess-corp.fr
3. 3Thess - Wikidatawikidata.org